Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.

Diabetes care

Volumn 32 Suppl 2, Issue , 2009, Pages

  Bianchi, Cristina ^a   Miccoli, Roberto ^a   Daniele, Giuseppe ^a   Penno, Giuseppe ^a   Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; ENZYME INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

BLOOD; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; MORTALITY; ORAL DRUG ADMINISTRATION; REVIEW; SECRETION;

ADMINISTRATION, ORAL; ALPHA-GLUCOSIDASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENZYME INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MYOCARDIAL INFARCTION; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

MLCS; MLOWN;

EID: 75549087002     PISSN: None     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-s336     Document Type: Review

References (53)